New cancer clinical trial: GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Published on: December 22, 2025 at 12:00PM
Conditions: Alveolar Soft Part Sarcoma; Renal Cell Carcinoma; Triple Negative Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Biological: GCAR1
Sponsors: Canadian Cancer Trials Group
Not yet recruiting
https://ift.tt/Sh1Eg5k GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours